Innodata Beats Q3 2026 Estimates as Revenue Rises 53% to $95.6M
Revenue of $95.6M vs. $83.3M expected and adjusted EPS of $0.29 vs. $0.17; revenue up 53% from a year earlier.
Innodata (INOD) beat estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $95.6 million, up 53% from a year earlier, above the $83.3 million estimate, and adjusted EPS was $0.29, up 21% from a year earlier, above the $0.17 estimate.
Shares rose 1.3% in after-hours trading as of 4:05 p.m. ET, to $39.14 from a $38.62 close.
Q3 2026 scorecard
| Parameters | Expected | Actual | Beat/Miss |
|---|---|---|---|
| Adjusted EPS | $0.17 | $0.29 | Beat by 72% |
| Revenue | $83.3M | $95.6M | Beat by 15% |
| Change | YoY | QoQ |
|---|---|---|
| Adjusted EPS | ▲ 21% | ▼ 29% |
| Revenue | ▲ 53% | ▲ 3.8% |
By our calculation, revenue was $12.3 million above the estimate and adjusted EPS was $0.12 above it. The QoQ column compares with the previous quarter's revenue of $92.1 million and adjusted EPS of $0.41. The YoY column compares with $62.5 million and $0.24 in the same quarter a year earlier.
Track record
- EPS record. Adjusted EPS beat the estimate in 8 of the last 8 reports, including this one.
- Revenue record. Revenue beat the estimate in 6 of the last 8 reports.
- Revenue trend. Revenue over the last 5 reports, oldest first: $62.5 million, $72.4 million, $90.1 million, $92.1 million and $95.6 million.
What to watch
- Next-quarter estimates. Consensus calls for EPS of $0.23 and revenue of $92.1 million next quarter, based on 2 analysts.
- Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 53% increase to $95.6 million.
- Estimate record. Whether Innodata extends a record of beating EPS estimates in 8 of its last 8 reports.
- Related coverage. See our reports on ICF International, Halozyme Therapeutics, Guardian Pharmacy Services and Guardant Health.
Sources: Results are from Innodata's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Innodata's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.
Readers also read
ICF International Q3 2026 EPS Tops Estimates at $1.98, but Revenue Misses at $470.5M
EarningsHalozyme Therapeutics Beats Q3 2026 Estimates as Revenue Rises 39% to $493.0M
EarningsGuardian Pharmacy Services Beats Q3 2026 Estimates as Revenue Falls 1.7% to $371.1M
EarningsGuardant Health Beats Q3 2026 Estimates as Revenue Rises 36% to $361.0M
MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.
